Product Growth Leverage rapid YUTREPIA sales momentum with a quarterly revenue trajectory showing significant year-over-year growth to align with payer discussions, reimbursement pathway optimization, and expanding market access opportunities in PAH and PH-ILD.

Strategic Expansion Capitalize on strong conferences and poster presentations at ERS 2026 and PHA 2026 to generate outbound follow-ups with key investigators, hospitals, and health systems looking to adopt advanced inhalation therapies and novel nebulized treprostinil formulations.

IP and Partnerships Monitor and address patent disputes while exploring collaboration or licensing discussions to mitigate commercialization risk, pursue co-development or regional partnerships, and protect competitive positioning in pulmonary disease treatments.

Financial Readiness Utilize solid recent profitability signals (net income and EBITDA uplift) and a sizable funding runway to support market expansion plans, payer negotiations, and potential strategic acquisitions or alliances.

Evidence Driven Highlight ongoing clinical and real-world data generation from PRINT technology and L606 development to support value propositions for health systems, payers, and specialty pharmacies, expanding addressable markets beyond PAH to related pulmonary vascular conditions.